Table S1 Treatment-related AEs in patients with IMDC I/P-risk sRCC.

Treatment-related AEs[a]	NIVO+IPI (n=73)		SUN (n=65)	
	Any grade	Grade 3–4	Any grade	Grade 3–4
Treatment-related AEs in ≥20% of patients in either arm, n (%)				
Patients with any event	71 (97.3)	36 (49.3)	63 (96.9)	29 (44.6)
Fatigue	34 (46.6)	6 (8.2)	32 (49.2)	4 (6.2)
Pruritus	23 (31.5)	0	5 (7.7)	0
Diarrhea	18 (24.7)	2 (2.7)	24 (36.9)	1 (1.5)
Rash	18 (24.7)	2 (2.7)	6 (9.2)	0
Nausea	17 (23.3)	3 (4.1)	18 (27.7)	0
Arthralgia	15 (20.5)	1 (1.4)	3 (4.6)	0
Dysgeusia	4 (5.5)	0	18 (27.7)	0
Mucosal inflammation	3 (4.1)	0	21 (32.3)	4 (6.2)
Palmar-plantar erythrodysesthesia	1 (1.4)	1 (1.4)	21 (32.3)	3 (4.6)
Hypertension	1 (1.4)	0	16 (24.6)	4 (6.2)
Treatment-related select AEs,[b] n (%)				
Skin	39 (53.4)	3 (4.1)	27 (41.5)	3 (4.6)
Endocrine	27 (37.0)	7 (9.6)	12 (18.5)	0
Gastrointestinal	18 (24.7)	2 (2.7)	24 (36.9)	1 (1.5)
Hepatic	16 (21.9)	7 (9.6)	7 (10.8)	3 (4.6)
Renal	9 (12.3)	0	4 (6.2)	1 (1.5)
Pulmonary	7 (9.6)	0	0	0
Treatment-related AEs leading to discontinuation, n (%)				
All patients with an event	16 (21.9)	14 (19.2)	8 (12.3)	6 (9.2)

[a]Includes events reported between first dose and 30 days after last dose of study therapy.
[b]Treatment-related select AEs were prespecified and defined as events that might be immune-mediated.
AE, adverse event; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; I/P, intermediate/poor; NIVO+IPI, nivolumab plus ipilimumab; sRCC, advanced renal cell carcinoma with sarcomatoid features; SUN, sunitinib.